

Special Issue

Development of Targeted Therapies for the Clinical Management of Cancer

Message from the Guest Editor

The development of targeted therapeutics has revolutionized the approach to targeting cancer in a way that minimizes the adverse side-effects associated with broad-spectrum applications. For example, small molecule enzyme inhibitors and monoclonal antibodies can be designed to target the specific biomolecules involved in tumorigenic cascades. In this Special Issue of *Sci*, we invite papers related to the design, development, testing, and regulatory approval pathways associated with targeted oncology therapeutics.

Guest Editor

Dr. Mark A. Brown

College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1005 Campus Delivery, Fort Collins, CO 80523, USA

Deadline for manuscript submissions

closed (15 October 2020)



Sci

an Open Access Journal
by MDPI

CiteScore 5.2
Tracked for Impact Factor



mdpi.com/si/38920

Sci
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
sci@mdpi.com

mdpi.com/journal/

[sci](https://mdpi.com/journal/sci)





Sci

an Open Access Journal
by MDPI

CiteScore 5.2
Tracked for Impact Factor



[mdpi.com/journal/
sci](https://mdpi.com/journal/sci)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Claus Jacob
Division of Bioorganic Chemistry, School of Pharmacy, Saarland
University, D-66123 Saarbruecken, Germany

Author Benefits

High Visibility:

indexed within ESCI (Web of Science), Scopus, and other
databases.

Journal Rank:

CiteScore - Q1 (Multidisciplinary)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 36.6 days after
submission; acceptance to publication is undertaken in 6.8
days (median values for papers published in this journal in
the first half of 2025).